Core Viewpoint - The announcement details the completion of a tender offer by Duori Pharmaceutical, with significant share acquisition by key individuals, leading to a majority stake in the company [1] Group 1: Tender Offer Details - Duori Pharmaceutical disclosed the tender offer report on January 21, 2026 [1] - The tender offer period ended on February 24, 2026 [1] - Wang Qingtai accepted a total of 17,600,600 shares, while Cao Xiaobing accepted 1,851,400 shares during the tender offer [1] Group 2: Shareholding Impact - Following the completion of the tender offer, the acquirer and their concerted parties hold a total of 43,120,000 shares [1] - This represents 53.90% of the total share capital of the listed company [1] Group 3: Stock Resumption - The company has applied to the Shenzhen Stock Exchange for the resumption of its stock trading [1] - Trading is set to resume on February 27, 2026 [1]
多瑞医药：要约收购结果已确认，股票复牌